BioNexus Gene Lab
Business Services · Malaysia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Vertical Business Suite Ii Bangsar 1...Phone Number
+60 374940760Website
www.bionexusgenelab.comRevenue
$5.3 MillionStock Symbol
BGLCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BioNexus Gene Lab
BioNexus Gene Lab Corporation (BGLC) applies less - invasive blood - based dynamic genome screening analysing changes in ribonucleic acid (RNA) predicting certain predisposed diseases even before they show any symptoms. This blood test provides very early detection of a person’s susceptibility to certain diseases enabling the person to take appropriate measures to stay healthy.Explore more
BioNexus Gene Lab Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioNexus Gene Lab your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BioNexus Gene Lab recently announced quarterly report
Click to see if BioNexus Gene Lab had a recent Job posting/layoffs
Funding: Get notified immidiatlly once BioNexus Gene Lab has new funding data
BioNexus Gene Lab, which may be a good buyer, showed buying intent in Masked Content Topic
Check if BioNexus Gene Lab has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at BioNexus Gene Lab
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when BioNexus Gene Lab launches new products
Check out if BioNexus Gene Lab is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
BioNexus Gene Lab is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioNexus Gene Lab is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioNexus Gene Lab.
BioNexus Gene Lab financials insights
Gather financial insights about BioNexus Gene Lab, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$5.8M
2025
Stock/Share Issuance
$500M
BioNexus Gene Lab Tech Stack
A closer look at the technologies used by BioNexus Gene Lab
Most Recent Scoops
Funding
Funding
Partnership
Partnership, Business Development, Software, Share Placement, Medical Research, Artificial Intelligence
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Earnings
Business Development
BioNexus Gene Lab News & Media
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelion is a precision diagnostics company focused on advancing next-generation oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays. Fidelion serves as the international intellectualBioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation frameworkBioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform. This phase marks the transition of VitaGuard™ from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacyBioNexus Gene Lab takes 15% stake in Fidelion, wins ASEAN rights | BGLC Stock News
Deal gives BGLC a dual-asset model: exclusive ASEAN VitaGuard MRD rights plus a 15% Fidelion stake, while Fidelion now owns 16.6% of BGLC via share swap.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding BioNexus Gene Lab
Sign Up For FreeTo access detailed company insights
BioNexus Gene Lab Corporation (BGLC) applies less - invasive blood - based dynamic genome screening analysing changes in ribonucleic acid (RNA) predicting certain predisposed diseases even before they show any symptoms. This blood test provides very early detection of a person’s susceptibility to certain diseases enabling the person to take appropr... Read More
